Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study.

What Was Tested

This randomized controlled trial looks at Glucagon.

Glucagon-like peptide-1 (GLP-1) originates from the gastrointestinal system in response to the presence of nutrition in the intestinal lumen and potentiates postprandial insulin secretion.

Also, it acts as an immune-modulator which has influences on cell-mediated immunity.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Twenty-four naive patients with acute thromboembolic cerebrovascular events, with National Institute of Health (NIH) stroke scores between 12 and 16, were included.

How the Study Was Run

The design is described as randomized and single-blind.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Glucagon was given.

The study was designed as a prospective, single-blinded study and carried out in the neurology intensive care unit (ICU) of a university hospital.

Any condition interfering with GLP-1 and immunity was regarded as exclusion criterion.

What Was Measured

Glucagon-like peptide-1 (GLP-1) originates from the gastrointestinal system in response to the presence of nutrition in the intestinal lumen and potentiates postprandial insulin secretion.

Topics PubMed links to this paper include Biomarkers, Enteral Nutrition, Glucagon-Like Peptide 1, Immunity, Cellular and Intensive Care Units.

What This Means in Plain Language

The paper is a randomized and single-blind study of Glucagon.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Critical care (London, England)), a journal based in England.

More context: the Glucagon compound page, all human trials.